Pfizer Inc. (PFE) Q1 2026 (USD): adj. EPS 0.75 (exp. 0.72), Revenue 14.5bln (exp. 13.84bln). Reaffirms Guidance: Current FY EPS 2.80-3.00 (exp. 2.96), Current FY Rev. 59.5-62.5bln (exp. 61.38bln)

Vyndamax Patent Settlements: Prev. exp. a "significant decline" in US revenue for Vyndamax from 2029, however, the settlement means revenue is seen as stable through mid-2031. CEO "Off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts ... particularly encouraged by what we're seeing in oncology and obesity, two areas where I believe Pfizer is positioned to lead.”